Our Products
Committed to engineering a healthier future
Diabetic Foot Infection*
The technology use in our product consists in an innovative bacteriophage cocktail with a broad host range, composed by 5 different phage's, developed for the treatment of diabetic foot infections, specifically target the bacteria's Staphylococcus aureus, Pseudomonas aeruginosa and Acinetobacter baumannii. The product provides an effective anti-infective treatment for chronic wound infections and contributes to antibiotic stewardship by decreasing the use of systemic antibiotics.
Granted with the Fast Track Designation by the FDA for the treatment of diabetic foot ulcers infected, our product is presently in a Phase IIb clinical trial of its development, and it is planned to be available in the market in 2025.
The content on this website page contains images and visual material that may be disturbing or upsetting to some viewers.
By proceeding, you acknowledge that you have been informed of the nature of the content and accept full responsibility for your experience on this site.
Respiratory Infection*
The tecnology envolves a bacteriophage cocktail aims to provide a hospital-based add-on therapy to the standard of care given by inhalation.
Our treatment-oriented assessment of the underlying nosocomial infection will be performed after cross-checking of the medical data, and results of the complementary diagnostic procedures.
Blepharitis*
Our product (LX24OP01) is directed to the field of bacteriophage treatment and
control of bacterial infections resistant to antibiotics in the ocular surface of the
eye, including conjunctiva, eyelids, eyelashes, glands and particularly in
blepharitis.
More specifically, our product relates to a novel cocktail of bacteriophages in an
eye drops solution having a high specificity against Staphylococcus aureus and
Pseudomonas aeruginosa strains.
Diabetic Retinophaty*
Our product (LX24OP02) is being developed for the treatment of age-related
macular degeneration (AMD), diabetic retinopathy (DR) and diabetic macular
edema (DME).
It relates to a novel fixed combination in an eyedrop formulation of a
monoclonal antibody fragment with the expression, affinity and solubility of a
conventional antibody plus a corticosteroid.
The anti-angiogenic compound inhibits the action of vascular endothelial growth
factor (VEGF), and the corticosteroid has the action of reducing vascular leakage, both anti-VEGF and corticoid encapsule and delivery through a selected
nanoliposomes particles in an eyedrops topical solution.
The anti-angiogenic compound inhibits the action of vascular endothelial growth factor (VEGF), and the corticosteroid has the action of reducing vascular leakage, both anti-VEGF and corticoid encapsulated are transported and released through selected nanoliposomes particles in an eye drop.
Atopic Dermatitis*
Our product (LX24DE01) is being developed to be a novel topical cream for the treatment of atopic dermatitis, which in a single product, offers a unique fixed combination of high efficacy of corticosteroids combined with a cocktail of bacteriophage against Staphylococcus aureus for an excellent treatment convenience.
For these reasons, LX24DE01 will offer a distinctive advantage for the topical
treatment of atopic dermatitis.
Pipeline
*Source: Lxbio data on file
